1192 related articles for article (PubMed ID: 22169129)
1. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
[TBL] [Abstract][Full Text] [Related]
2. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
[TBL] [Abstract][Full Text] [Related]
4. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
5. Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease.
Yunoki K; Nakamura K; Miyoshi T; Enko K; Kubo M; Murakami M; Hata Y; Kohno K; Morita H; Kusano KF; Ito H
Am J Cardiol; 2011 Aug; 108(3):333-9. PubMed ID: 21545981
[TBL] [Abstract][Full Text] [Related]
6. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
Miller M; Ginsberg HN; Schaefer EJ
Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
8. [High and low density lipoprotein abnormalities in coronary patients with LDL-C at target and uncontrolled HDL-C and triglycerides].
Posadas-Romero C; Posadas-Sánchez R; Juárez-Rojas JG; Medina-Urrutia A; Jorge-Galarza E; Cardoso-Saldaña G; Caracas-Portilla N; Mendoza-Peŕez E
Arch Cardiol Mex; 2008; 78(1):30-9. PubMed ID: 18581711
[TBL] [Abstract][Full Text] [Related]
9. [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study].
González-Juanatey JR; Cordero A; Vitale GC; González-Timón B; Mazón P; Bertomeu V
Rev Esp Cardiol; 2011 Oct; 64(10):862-8. PubMed ID: 21835533
[TBL] [Abstract][Full Text] [Related]
10. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care.
Bestehorn K; Smolka W; Pittrow D; Schulte H; Assmann G
Curr Med Res Opin; 2010 Dec; 26(12):2833-9. PubMed ID: 21058895
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
Liberopoulos E; Vlasserou F; Mitrogianni Z; Papageorgantas I; Elisaf M;
Angiology; 2012 Apr; 63(3):184-93. PubMed ID: 21676964
[TBL] [Abstract][Full Text] [Related]
13. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
14. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.
O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM
Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307
[TBL] [Abstract][Full Text] [Related]
17. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
Gotto AM
Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
[TBL] [Abstract][Full Text] [Related]
19. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
20. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
